MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT AND WELCOMES NEW CFO

DENVER, Sept. 23, 2022 /CNW/ - Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that, in connection with its previously announced Common Share Subscription Agreement (the "Subscription Agreement") with a third-party investor dated August 26, 2022 and the subsequent filing of a shelf prospectus supplement (the "Prospectus Supplement") in connection therewith on September 7, 2022, the Company has closed the second tranche of the first issuance under the Subscription Agreement (the "Offering"). The Company is also pleased to announce the appointment of John Ross as its Chief Financial Officer (CFO).